Adis summary of research: Long-term safety and tolerability of daridorexant in patients with insomnia disorder

Daridorexant, a dual orexin receptor antagonist (DORA), improved sleep outcomes in adults with insomnia disorder in two pivotal 12-week phase 3 trials. DORAs specifically target the brain's orexin system, which regulates the sleep-wake cycle, thereby avoiding broader inhibition of neuronal pathways and associated adverse effects. This Adis Summary of Research reports the findings of a 40-week double-blind extension study that assessed the long-term safety and tolerability of daridorexant in patients who completed the pivotal trials.